Loading
The first PD-L1 antibody trial treated 207 people across several cancers; melanoma, kidney and lung cancers responded, and none of the 14 pancreatic cancer patients did.
In a multicentre phase 1 trial, intravenous anti-PD-L1 antibody at 0.3 to 10 mg/kg was given every 14 days in 6-week cycles for up to 16 cycles to patients with selected advanced cancers. Of 207 patients, 75 had non-small-cell lung cancer, 55 melanoma, 18 colorectal, 17 renal cell, 17 ovarian, 14 pancreatic, 7 gastric and 4 breast cancer. Grade 3 or 4 treatment-related toxicity occurred in 9%. Objective responses were seen in 9 of 52 melanoma, 2 of 17 renal cell, 5 of 49 lung and 1 of 17 ovarian patients; no pancreatic responses were reported.
The trial that opened the PD-L1 era for other cancers is also the first evidence that pancreatic cancer would be left out of it.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Metastatic pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, Pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, Pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.